Sanofi-Synthelabo Tirapazamine NDA Expected In 2003; ADSs Traded On NYSE
Executive Summary
Sanofi-Synthelabo expects to file a tirapazamine NDA in late 2003 for the treatment of non-small cell lung cancer, the company said in a 1registration statement filed with the Securities & Exchange Commission